BTIG analyst Justin Zelin maintained a Buy rating on 89bio (ETNB – Research Report) yesterday and set a price target of $37.00. The company’s shares closed last Friday at $11.17.
Zelin covers the Healthcare sector, focusing on stocks such as Legend Biotech, Viking Therapeutics, and 89bio. According to TipRanks, Zelin has an average return of 8.3% and a 45.86% success rate on recommended stocks.
89bio has an analyst consensus of Strong Buy, with a price target consensus of $28.67, implying a 156.67% upside from current levels. In a report released on December 20, H.C. Wainwright also maintained a Buy rating on the stock with a $32.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on 89bio’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $34.73 million. In comparison, last year the company had a GAAP net loss of $26.81 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
89bio (ETNB) Company Description:
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
Read More on ETNB:
- 89bio price target lowered to $32 from $35 at H.C. Wainwright
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- 89bio 15.135M share Spot Secondary priced at $9.25
- 89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants
